Regular ArticleComparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome☆
Section snippets
Subjects
Thirty-six patients with unstable angina pectoris or non-ST-elevation myocardial infarction were included in the study. From each patient blood was sampled on four occasions: acute (sample 1, i.e. at admission to coronary care unit), 24 h after admission (sample 2), and 3 (sample 3) and 6 months (sample 4) after admission. During the course of the study two patients died and two withdrew from the study, one after the second sampling and one after the third sampling.
Patients with severe
Results
Statistically significant correlations (p < 0.01, N = 150) between the immunoassays and the functional assay were observed [r2 = 0.67 and 0.47 for Asserachrom and Haemochrom, respectively (Fig. 1). The regression functions were 0.64x + 21.6 and 0.65x + 11.7 for Asserachrom and Haemochrom, respectively. Of the three assays the Pefakit values were higher within the measurement interval than those of the immunoassays of which the Asserachrom gave higher results than the Haemochrom assay (Fig. 2). Since the
Discussion
The samples used in the present study are from a survey of hemostasis and inflammatory markers in patients with acute coronary syndrome in which e.g. the acute phase reactants fibrinogen and CRP are studied [18]. In the present report, we focus on the measurement of TAFI concentrations with assays based on different principles. The immunoassays measure the plasma concentration of total TAFI antigen or the pro-TAFI antigen, only, whereas the functional assay measures the TAFI activity
Conclusion
Our study shows that the virtual concentration and course of TAFI concentration changes during an acute coronary event and the convalescence depend on the measurement principle and method. The kinetic assay principle with high precision and easy performance speaks in favor of the chromogenic assay based on determination of TAFI activity concentration corresponding to the concentration of pro-TAFI. On the other hand, the availability of a traceable calibrator in the Asserachrom kit combined with
Acknowledgements
We are particularly grateful to Nida Soutami and Ingrid Jacobsson for their skilful performance of all analysis and Professor Margareta Blombäck for continued support and advice. We would also like to thank Barry Woodhams and Olivier Morboeuf from Diagnostica Stago for supplying Asserachrom kits and useful suggestions. The cost of one month's laboratory work (laboratory technician) was paid by Diagnostica Stago.
References (19)
- et al.
Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
J Biol Chem
(1995) - et al.
Thrombin-activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
Blood
(2000) - et al.
Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism
Blood
(2004) - et al.
High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke
J Thromb Haemost
(2005) - et al.
Very high TAFI antigen levels are associated with a lower hard core coronary events: the PRIME Study
J Thromb Haemost
(2003) Thrombin activatable fibrinolysis inhibitor (TAFI) a link between coagulation and fibrinolysis (review)
Clin Lab
(2003)- et al.
Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors
Arterioscler Thromb Vasc Biol
(2000) - et al.
Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke
Stroke
(2003) - et al.
Plasma procarboxypeptidase U in men with symptomatic coronary artery disease
Thromb Haemost
(2000)
Cited by (0)
- ☆
Financial support for this investigation was obtained from the Heart and Lung Foundation Sweden, Stiftelsen Serafimerlasarettet, Karolinska Institutet foundation no. 176.